Related Experiment Video
Updated: Jul 24, 2026
14:19
Primary Outcome Assessment in a Pig Model of Acute Myocardial Infarction
Published on: October 14, 2016
11.5K
PET and Cardiac Amyloidosis: Which Possible Role?
Alberto Aimo1, Yu Fu Ferrari Chen2, Vincenzo Castiglione3
1Interdisciplinary Center for Health Sciences, Scuola Superiore Sant'Anna, Pisa 56127, Italy; Fondazione Toscana Gabriele Monasterio, Pisa 56125, Italy.
PET Clinics
|June 11, 2025
Summary
Positron Emission Tomography (PET) with 18F-labeled tracers shows potential for diagnosing and differentiating cancer (CA). These tracers can quantify disease severity and monitor treatment response effectively.
Area of Science:
- Nuclear Medicine
- Oncology
- Radiochemistry
Background:
- Positron Emission Tomography (PET) shows promise in cancer (CA) diagnosis and differentiation.
- 18F-labeled tracers like 18F-flutemetamol, 18F-florbetapir, and 18F-florbetaben offer extended half-lives, reducing the need for on-site cyclotrons.
- PET amyloid-binding tracers have a higher affinity for light-chain fibrils than bone tracers, aiding in CA differentiation.
Purpose of the Study:
- To explore the capabilities of PET imaging in diagnosing and differentiating various forms of cancer (CA).
- To highlight the advantages of 18F-labeled tracers for PET imaging in oncology.
- To establish PET imaging as a tool for quantifying disease severity and monitoring treatment response.
Main Methods:
- Utilizing 18F-labeled tracers (e.g., 18F-flutemetamol, 18F-florbetapir, 18F-florbetaben) in PET scans.
- Employing both dynamic and static PET imaging methodologies.
- Measuring tracer uptake to quantify disease parameters.
Main Results:
- 18F-labeled tracers demonstrate promising capabilities in cancer diagnosis and differentiation.
- The extended half-life of these tracers simplifies logistical requirements for PET imaging.
- PET imaging allows for quantification of disease severity and assessment of treatment response.
Conclusions:
- PET imaging with 18F-labeled tracers is a valuable tool for cancer diagnosis and differentiation.
- The ability to quantify disease severity and monitor treatment response enhances clinical management of cancer.
- Further research into PET amyloid-binding tracers may lead to improved accuracy in differentiating CA types.
Related Concept Videos
03:03Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
03:03Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
01:25Cardiomyopathy I: Introduction and Classification
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
01:30Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...